Saturday, 31 October 2026European Markets

CASINO GUICHARD Shares Plummet 20% In Volatile Session: What's Next?

Loading stream...

(vianews) - investors in casino guichard (cac 40: co.pa) saw their shares tumble by an astounding 20.93% at 15:06 est on wednesday after three consecutive sessions of gains, falling under its 52-week high of eur10.14 set on february 11th. even so, it remains up 87.5% from its 52-week low of eur0.31, hit on march 19th. casino guichard was not alone in experiencing its stock price decline as cac 40 index, of which it forms part, also witnessed a 0.03% dip to eur7,945.86 at that same moment despite seeing an uptick earlier. overall, today's performance seems consistent with the bearish trend seen thus far on the exchange.

about casino guichard

casino, guichard-perrachon s.a. is a multinational retail company based in france that operates three main business segments: food retailing, banking and property development. their food retail operations include hypermarkets, supermarkets, shopping malls, e-commerce sites as well as convenience, discount and cash and carry stores; it also engages in digital marketing services, service station franchise agreements, real estate asset management property development trading rental banking banking energy-related activities among others. established in 1898 at their saint-etienne headquarters they operate throughout france latin america and internationally through rallye sa who are their parent company's subsidiaries.

yearly analysis

as per available data, casino guichard stock is trading at eur0.56 which is far below its 52-week high of eur10.14, yet significantly above its 52-week low of eur0.38. as for sales growth, casino guichard expects its sales growth for this year and next to be negative 4.8% and 21.9% respectively. overall, the 52-week high and low values for casino guichard stock are eur10.14 (52-week high) and eur0.38 (52-week low), with anticipated sales growth for both this year and next being negative 4.8% and 21.9%, respectively.

technical analysis

casino guichard's stock is experiencing an alarming decline, falling below both its 50-day and 200-day moving averages. furthermore, last reported volume is 101.51% above its average volume of 942678; suggesting more trading activity compared to normal. volatility for this stock has been relatively low over the past quarter, averaging an intraday variation of only 5.61% on average. nonetheless, its highest average amplitude volatility value reached 16.91% within one week; suggesting potential increased volatility over time. stochastic oscillator, a widely-used indicator of overbought and oversold conditions, shows that casino guichard stock may currently be oversold (=20). this could signal undervaluation or an upcoming price rebound in its stock price. overall, investors should closely follow casino guichard's stock price and volume activity, as well as volatility and oscillator indicators to make informed decisions about whether to purchase or sell its shares.

quarter analysis

earnings growth in the last year, casino guichard's earnings have seen significant year-on-year growth of 12.5%. dividend yieldthe company currently boasts an above-industry average dividend yield at 4.1%. stock price casino guichard's share price has experienced significant fluctuations over the past year, fluctuating between eur25.5 and eur19.2. valuation based on earnings and revenue growth analysis, casino guichard currently trades with an earnings to revenue ratio of 13.8, which is significantly below industry norms. industrycasino guichard operates within the retail industry, which has recently experienced several challenges due to e-commerce trends and changing consumer tastes. however, the company has made strides toward expanding their online presence and improving store experiences so as to remain competitive and stay profitable. outlookdespite experiencing negative sales growth for the next quarter, casino guichard's overall revenue and earnings growth has been positive, while their dividend yield remains attractive to income investors. while retail industry challenges exist, casino guichard may find success by expanding online presence and improving store experience which may allow the company to remain competitive over time.

equity analysis

according to available information, casino guichard appears to have performed poorly in terms of profitability. a negative eps of eur-20.53 suggests losses over the last year while its negative return on equity of -65.71% indicates it failed to generate sufficient returns to compensate its shareholders adequately for their investment in it. investors should exercise extreme caution when investing in companies with poor profitability indicators, as this could indicate difficulties generating revenue or managing expenses effectively. a thorough investigation must take place, including reviewing financial statements, industry trends and competitive landscape data to ascertain why their profitability levels have taken a dip while also assessing future potential growth and profits of such an enterprise.

more news about casino guichard (co.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com